The report on the global 23 valent pneumococcal polysaccharide vaccine market provides qualitative and quantitative analysis for the period from 2021-2030. The global 23 valent pneumococcal polysaccharide vaccine market was valued at USD 2.11 billion in 2022 and is expected to reach USD 4.21 billion in 2030, with a CAGR of 9.06% during the forecast period 2023-2030. The study on 23 valent pneumococcal polysaccharide vaccine market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.
The report on 23 valent pneumococcal polysaccharide vaccine market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global 23 valent pneumococcal polysaccharide vaccine market over the period of 2021-2030. Moreover, the report is a collective presentation of primary and secondary research findings.
Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global 23 valent pneumococcal polysaccharide vaccine market over the period of 2021-2030. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.
1. Key Opinion Leaders associated
2. Internal and External subject matter experts
3. Professionals and participants from the industry
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies
2. Complete coverage of all the segments in the 23 valent pneumococcal polysaccharide vaccine market to analyze the trends, developments in the global market and forecast of market size up to 2030.
3. Comprehensive analysis of the companies operating in the global 23 valent pneumococcal polysaccharide vaccine market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
The report on 23 valent pneumococcal polysaccharide vaccine market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global 23 valent pneumococcal polysaccharide vaccine market over the period of 2021-2030. Moreover, the report is a collective presentation of primary and secondary research findings.
Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global 23 valent pneumococcal polysaccharide vaccine market over the period of 2021-2030. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.
Report Findings
1) Drivers
- The 23-valent pneumococcal polysaccharide vaccine market is driven by the increasing geriatric population.
- Rising government initiatives and vaccination programs fuel the market growth.
2) Restraints
3) Opportunities
- The pricing issues make the vaccine less accessible, particularly in low-income regions can act as a barrier to the market growth.
- The continued expansion of vaccination programs, in developed and developing regions, presents a prominent opportunity for market growth.
Research Methodology
A) Primary Research
The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include1. Key Opinion Leaders associated
2. Internal and External subject matter experts
3. Professionals and participants from the industry
The primary research respondents typically include
1. Executives working with leading companies in the market under review2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.
B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.The secondary sources of the data typically include
1. Company reports and publications2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies
Segment Covered
The global 23 valent pneumococcal polysaccharide vaccine market is segmented on the basis of type, age group, and distribution channel.The Global 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type
- Pre-filled Syringe
- Single Dose Vial
The Global 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group
- 2-10 Years
- 10-64 Years
- 64+ Years
The Global 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel
- Hospitals
- Clinics
- Others
Company Profiles
The companies covered in the report include- Merck & Co., Inc.
- GSK plc.
- Walvax Biotechnology Co., Ltd.
- Zhi Fei Biological
- SINOVAC
- Chengdu Institute of Biology (CIB)
- Sanofi
- Pfizer Inc.
- Beijing Minhai Biological Technology Co., Ltd.
- Serum Institute of India Pvt. Ltd.
What does this Report Deliver?
1. Comprehensive analysis of the global as well as regional markets of the 23 valent pneumococcal polysaccharide vaccine market.2. Complete coverage of all the segments in the 23 valent pneumococcal polysaccharide vaccine market to analyze the trends, developments in the global market and forecast of market size up to 2030.
3. Comprehensive analysis of the companies operating in the global 23 valent pneumococcal polysaccharide vaccine market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Preface
Chapter 2. Executive Summary
Chapter 3. Global 23 Valent Pneumococcal Polysaccharide Vaccine Market Overview
Chapter 5. Company Profiles and Competitive Landscape
Chapter 6. Global 23 Valent Pneumococcal Polysaccharide Vaccine Market by Type
Chapter 7. Global 23 Valent Pneumococcal Polysaccharide Vaccine Market by Age Group
Chapter 8. Global 23 Valent Pneumococcal Polysaccharide Vaccine Market by Distribution Channel
Chapter 9. Global 23 Valent Pneumococcal Polysaccharide Vaccine Market by Region 2023-2030
Companies Mentioned
- Merck & Co., Inc.
- GSK plc.
- Walvax Biotechnology Co., Ltd.
- Zhi Fei Biological
- SINOVAC
- Chengdu Institute of Biology (CIB)
- Sanofi
- Pfizer Inc.
- Beijing Minhai Biological Technology Co., Ltd.
- Serum Institute of India Pvt. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 255 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 2.11 Billion |
| Forecasted Market Value ( USD | $ 4.21 Billion |
| Compound Annual Growth Rate | 9.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
